title: Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
authors.forename: Bulent
authors.initials: B
authors.lastname: Yalcin
authors.forename: Abdullah
authors.initials: A
authors.lastname: Buyukcelik
authors.forename: Samet
authors.initials: S
authors.lastname: Yalcin
authors.forename: Gungor
authors.initials: G
authors.lastname: Utkan
authors.forename: Hatice
authors.initials: H
authors.lastname: Doruk
authors.forename: Mutlu
authors.initials: M
authors.lastname: Dogan
authors.forename: Mehmet
authors.initials: M
authors.lastname: Altan
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D015986:Confounding Factors, Epidemiologic; D051546:Cyclooxygenase 2; D004311:Double-Blind Method; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D008565:Membrane Proteins; D015663:Osteoporosis, Postmenopausal / Q000150:complications*; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects*; D013923:Thromboembolism / Q000139:chemically induced*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases